Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.
about
K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory ArthritisInduction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate ImmunityThe role of Fc-FcγR interactions in IgG-mediated microbial neutralizationImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesThe European Hematology Association Roadmap for European Hematology Research: a consensus documentHeme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin.Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.Sialic acids and autoimmune disease.The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritis.Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.Fcγ receptor pathways during active and passive immunization.Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.IVIG-mediated effector functions in autoimmune and inflammatory diseases.Immunoglobulin Glycosylation Effects in Allergy and Immunity.The Role and Function of Fcγ Receptors on Myeloid Cells.Anti-retroviral antibody FcγR-mediated effector functions.Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization.Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?The direct and indirect effects of glycans on immune function.Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins.Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease.Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?Fcγ Receptor Function and the Design of Vaccination Strategies.Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases.Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.Integrated Genome and Protein Editing Swaps α-2,6 Sialylation for α-2,3 Sialic Acid on Recombinant Antibodies from CHO.Diversification of IgG effector functions.The Role of Fc Gamma Receptors in Broad Protection against Influenza Viruses
P2860
Q26745541-F484CBDD-C775-45FC-A99B-D726D123A5B7Q26781290-A06CD043-0B0F-474D-8AC3-A00D47E23717Q26797466-5A53EE55-7FD8-4294-8C88-A46759C84BCDQ28069362-D97312D2-0DC9-4360-8BCA-AC7C8EA3B51CQ28830861-9ABE02DB-0192-429A-BCA6-772672CB5683Q36500575-BCB4A648-0498-42B2-AB9F-2C9A00E6F3A4Q36592223-D5F93787-08F3-4D9F-9A6B-9BAA946F1B9EQ36625410-B8C07D95-D45D-420E-BA3B-A024F62C1E4CQ36976399-3546BFD6-828D-4528-AF91-B34DAB67AA17Q37713650-DA1F5ABD-91AB-4670-81D4-55314C07C00AQ38615353-264A362C-0892-4EC7-BD10-DCB372B7187FQ38615357-7EFED3D6-FEF5-4388-8E85-95B607B7B741Q38615376-BCFC6861-7B7A-4594-A51F-F2AFE34BED5EQ38699812-EBDA6700-CD0C-4CFD-AEB5-B39036A5279BQ38994739-AF8088AD-5F20-42FC-9D3F-0B6D4A5D0283Q39088502-DDA2EB27-4441-467C-A59C-A704788B4869Q39108744-295861B8-E9B2-4E7E-BB95-850C361CBDEBQ40056879-229F7660-DC14-4AC5-BF1F-3AC505B93598Q42375731-9AA89D03-E1E1-4963-904A-1276A50F9AA8Q46632825-115EC7F7-6334-4D3F-A410-958712EF5C15Q47132349-DC5A0852-59DC-4AAE-90F1-16621F4BCC5EQ47220975-BD36F5CD-9EBC-4997-81B5-AAAF597EE0ACQ47804590-2EF3B785-0034-4AF7-BEDA-30598D72EB47Q47945550-56AF67B3-768C-416B-8581-A2FAE68A9771Q50138178-BCB63560-4F4D-4B12-A659-431E172B801CQ50193260-43124350-B074-438B-80A3-3006A209BDBDQ51081577-BBC90759-B749-4F0F-8BB6-F971E705DA80Q53313488-A95FDEBF-E20F-4DF0-873F-DD7D58A3AFD2Q57019841-6B1A79D8-0F82-4C79-9FBA-745072094D51
P2860
Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Protection in antibody- and T ...... IgG Fcs requires type II FcRs.
@ast
Protection in antibody- and T ...... IgG Fcs requires type II FcRs.
@en
type
label
Protection in antibody- and T ...... IgG Fcs requires type II FcRs.
@ast
Protection in antibody- and T ...... IgG Fcs requires type II FcRs.
@en
prefLabel
Protection in antibody- and T ...... IgG Fcs requires type II FcRs.
@ast
Protection in antibody- and T ...... IgG Fcs requires type II FcRs.
@en
P2093
P2860
P356
P1476
Protection in antibody- and T ...... IgG Fcs requires type II FcRs.
@en
P2093
Andrew Pincetic
Benjamin M Fiebiger
Jad Maamary
Jeffrey V Ravetch
P2860
P304
P356
10.1073/PNAS.1505292112
P407
P577
2015-04-13T00:00:00Z